# R1 Clinical-Safety Review — nodular_lymphocyte_predominant_hodgkin

VERDICT: APPROVE

Confidence: 90

Goldens changed: no (intended: n/a — narrative KB content, no engine/rule/dose logic touched)

Adversarial-verify verdict file (.verdict.md): NOT PRESENT. No prior adversarial ISSUES to reconcile.

## 1. Safety
No unsafe, misleading, or harmful directive found. Every therapeutic statement is hedged
("commonly", "recognised option", "when indicated", "in select cases") and routes decisions to
specialists. No absolute "always/never" that could mislead a clinician. The high-risk items are
handled correctly:
- Observation after complete excision of a solitary node is presented as an option "in some
  cases," not a blanket recommendation — matches real active-surveillance practice for NLPHL.
- Transformation to aggressive large B-cell lymphoma is flagged with a low re-biopsy threshold,
  which is the safety-relevant point for this indolent disease.

## 2. Grounding (DeVita 12th ed / NCCN standard of care)
Attribution is disciplined and honest:
- The B-cell lineage / CD20+ "popcorn" immunophenotype and the non-contiguous distant-spread
  pattern (isolated cervical node, low-grade-B-cell-like dissemination) are correctly attributed
  to DeVita Ch. 66 — these are genuinely in that chapter.
- All NLPHL-specific treatment claims (involved-site RT alone for localised disease, anti-CD20
  therapy for advanced/symptomatic disease, chemoimmunotherapy backbones, ASCT in select
  relapse, anthracycline-based therapy on transformation) are explicitly labelled "general
  oncology standard, not from DeVita's section on this disease." These are consistent with NCCN
  NLPHL standard of care. No fabricated regimen, trial, response rate, or survival statistic.
- The radiotherapy-consolidation / PET-guided de-escalation passage (lines 61-66) is attributed
  to DeVita as a general Hodgkin-lymphoma principle, which the grounding note (lines 13-16)
  already flags as CHL-context material. The draft is transparent that this is general HL
  guidance, not NLPHL-specific — clinically uncontroversial and correctly framed. Acceptable.

No claim is mis-attributed to DeVita.

## 3. Dose-free
CONFIRMED dose-free. No mg, mg/m2, AUC, cycle counts, or numbered schedules. The only numerals
are stage descriptors (I-II), antigen names (CD20, CD79a, PAX5, anti-PD-1), and the citation
(12th ed., Ch. 66). All appropriate; none are doses.

## 4. Scope
Appropriately scoped as decision-support. Consistently hedged, repeated referral triggers
(haemato-oncology, lymphoma pathology, radiation oncology), and an explicit "What DeVita does
not address" section. Does not diagnose definitively or prescribe.

## Critical
None.

## Important
None.

## Advisory
- Lines 61-66 lean on DeVita's general HL radiotherapy discussion while the disease is NLPHL;
  the framing is honest but a reader could momentarily read it as NLPHL-specific DeVita guidance.
  Optional: add the same "(general HL principle, not NLPHL-specific)" tag used elsewhere for full
  consistency. Not blocking.
